Pipeline Promise | Disc Medicine's bitopertin and DISC-0974 show potential in rare blood disorders, with NDA filing for bitopertin expected in late 2025 |
Market Opportunity | Expanded patient estimates for EPP/XLP and substantial anemia treatment market present significant revenue potential for Disc Medicine |
Catalysts Ahead | Key milestones include NDA filing, Phase 2 data readouts, and new trial initiations, potentially driving stock performance and valuation |
Analyst Optimism | Price targets range from $75 to $132, reflecting confidence in Disc Medicine's pipeline and market potential despite current unprofitability |
Metrics to compare | IRON | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipIRONPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.0x | −4.6x | −0.5x | |
PEG Ratio | 0.22 | −0.09 | 0.00 | |
Price/Book | 3.1x | 6.2x | 2.6x | |
Price / LTM Sales | - | 32.4x | 3.2x | |
Upside (Analyst Target) | 55.4% | 89.4% | 50.1% | |
Fair Value Upside | Unlock | −12.6% | 8.6% | Unlock |